Little is known about the impact of coronavirus disease 2019 (COVID-19) pandemic to the care of patients with systemic lupus erythematosus (SLE) in the long-term. By crossing population data with the results of a web-based survey focused on the timeframes January–April and May–December 2020, we found that among 334/518 responders, 28 had COVID-19 in 2020. Seventeen cases occurred in May–December, in parallel with trends in the general population and loosening of containment policy strength. Age > 40 years (p = 0.026), prednisone escalation (p = 0.008) and infected relatives (p < 0.001) were most significantly associated with COVID-19. Weaker associations were found with asthma, lymphadenopathy and azathioprine or cyclosporine treatment. Only 31% of patients with infected relatives developed COVID-19. Healthcare service disruptions were not associated with rising hospitalisations. Vaccination prospects were generally welcomed. Our data suggest that COVID-19 has a moderate impact on patients with SLE, which might be significantly modulated by public health policies, including vaccination.

关于 2019 年冠状病毒病 (COVID-19) 大流行对系统性红斑狼疮 (SLE) 患者护理的长期影响知之甚少。通过将人口数据与侧重于 2020 年 1 月至 4 月和 5 月至 12 月时间段的基于网络的调查结果进行交叉，我们发现在 334/518 名响应者中，28 人在 2020 年患有 COVID-19。17 例发生在 5 月至 12 月，与总人口的趋势和遏制政策力度的放松同时进行。年龄 > 40 岁 ( p  = 0.026)、强的松剂量增加 ( p  = 0.008) 和受感染的亲属 ( p < 0.001) 与 COVID-19 最显着相关。与哮喘、淋巴结肿大和硫唑嘌呤或环孢素治疗的关联较弱。只有 31% 的亲属感染的患者发展为 COVID-19。医疗服务中断与住院率上升无关。疫苗接种前景普遍受到欢迎。我们的数据表明，COVID-19 对 SLE 患者有中度影响，这可能会受到包括疫苗接种在内的公共卫生政策的显着调节。